FUNDAMENTALS · Fundamentals · TW Healthcare

Universal Vision Biotechnology (3218) Fundamentals 2026 — P/E 12.2x, Revenue Analysis | SniperIQ

Universal Vision Biotechnology (3218) is a TW-listed Healthcare company in Medical - Care Facilities with a market capitalization of NT

1.7B, trading at NT
38.50 on the TWO. This SniperIQ fundamentals page covers Universal Vision Biotechnology's valuation (P/E 12.2x, P/B 3.3x), profitability (net margin 23.0%), revenue (NT$4.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT
1.7B
P/E (TTM)12.2x
Net Margin23.0%
Revenue (FY25)NT$4.2B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Universal Vision Biotechnology's market cap?

Universal Vision Biotechnology (3218) has a market capitalization of approximately NT

1.7B, trading at NT
38.50 on the TWO. Market cap moves with the live share price.

What is Universal Vision Biotechnology's P/E ratio?

Universal Vision Biotechnology's trailing twelve-month P/E ratio is 12.2x, with a price-to-book (P/B) of 3.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Universal Vision Biotechnology?

Universal Vision Biotechnology runs a net profit margin of 23.0%, a gross margin of 57.7%, and an operating margin of 31.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Universal Vision Biotechnology generate?

Universal Vision Biotechnology reported revenue of NT$4.2B for fiscal year 2025, with net income of NT

.0B and earnings per share (EPS) of 12.31. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Universal Vision Biotechnology pay a dividend?

Universal Vision Biotechnology offers a trailing dividend yield of about 5.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Universal Vision Biotechnology financially healthy?

Universal Vision Biotechnology carries a debt-to-equity ratio of 0.31x and a current ratio of 1.91x, with a market beta of 0.33. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Universal Vision Biotechnology a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Universal Vision Biotechnology (3218) the key facts are: market cap NT

1.7B, P/E 12.2x, revenue NT$4.2B, 52-week range 122-219.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Universal Vision Biotechnology's full fundamentals live

Get Universal Vision Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Zhejiang Medicine (600216) fundamentals · Great Tree Pharmacy (6469) fundamentals · Shanghai Shyndec Pharmaceutical (600420) fundamentals · Vizionfocus (4771) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons